Aeovian Pharmaceuticals
3 known investors
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
Biotech
Founders & leadership
AJ
Allison J. HulmeCEO & President
JK
John KincaidChief Scientific Officer
RG
Richard GasterDirector & Chairman
Investors · 3
In the news
- $55m funding boost for Aeovian to tackle TSC-related epilepsybioxconomy.com · 2025
- Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $55 Million Series B Financing | Wilson Sonsiniwsgr.com · 2025
- Aeovian Pharmaceuticals Raises $55M in Fundingfinsmes.com · 2025
- Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsybusinesswire.com · 2025
- Aeovian Pharmaceuticals Closes $50M Financingfinsmes.com · 2024
- Aeovian raises $37 million for mTORC1 inhibitorscen.acs.org · 2019